A First-In-Human Phase 1 Trial of T-Cell Membrane-Anchored Tumor Targeted Il12 (Attil12)- T-Cell Therapy in Subjects With Advanced/Metastatic Soft Tissue and Bone Sarcoma

Recruiting

Phase 1

attIL2-T Cell TherapyA First-In-Human Phase 1 Trial of T-Cell Membrane-Anchored Tumor Targeted Il12 (Attil12)- T-Cell Therapy in Subjects With Advanced/Metastatic Soft Tissue and Bone Sarcoma

Sponsor:

M.D. Anderson Cancer Center

Code:

NCT05621668

Conditions

Soft Tissue Sarcoma

Bone Sarcoma

Eligibility Criteria

Sex: All

Age: 12+

Healthy Volunteers: Not accepted

Interventions

Cyclophosphamide

attIL2-T cells

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-10-31. This information was provided to ClinicalTrials.gov by M.D. Anderson Cancer Center on 2025-10-20.